anandamide has been researched along with Fibromyalgia* in 2 studies
2 other study(ies) available for anandamide and Fibromyalgia
Article | Year |
---|---|
Increased Anandamide and Decreased Pain and Depression after Exercise in Fibromyalgia.
Physical exercise is increasingly being promoted by health care for chronic pain conditions with beneficial outcomes, such as pain and fatigue reduction, and increased quality of life. Nevertheless, knowledge about biochemical consequences of physical exercise in chronic pain is still relatively poor. The endocannabinoid system has been suggested to play a role for acute exercise-induced reward and pain inhibition. The aim of this study is to investigate the chronic outcomes of resistance exercise on levels of endocannabinoids and related lipids in fibromyalgia (FM).. This study examine the outcomes of a 15-wk person-centered resistance exercise program on plasma levels of the lipid mediators; anandamide, 2-arachidonoylglycerol (2-AG), oleoylethanolamide, palmitoylethanolamide, and stearoylethanolamide (SEA) sampled from 37 women with FM and 33 healthy controls. The associations between clinical scorings of pain, depression, anxiety, fatigue, and muscle strength with levels of these lipid mediators before and after the exercise program are also analyzed.. After the 15-wk exercise program, anandamide levels were significantly increased, and SEA levels significantly decreased in FM. Pain intensity and depression scorings decreased and muscle strength increased, and in a multivariate context, muscle strength was positively associated with 2-AG levels after the resistance exercise program in FM.. The increased anandamide and decreased SEA in women with FM after the 15-wk program might point to a chronic effect of resistance exercise. Pain and depression scorings decreased in the FM group after the program, but no associations between pain, depression, and lipid level changes were assured. Topics: Amides; Anxiety; Arachidonic Acids; Depression; Endocannabinoids; Ethanolamines; Exercise Therapy; Fatigue; Female; Fibromyalgia; Glycerides; Humans; Oleic Acids; Pain Management; Palmitic Acids; Polyunsaturated Alkamides; Resistance Training; Stearic Acids | 2020 |
Anandamide and neutrophil function in patients with fibromyalgia.
Fibromyalgia (FM) is a common stress-related painful disorder. There is considerable evidence of neuroimmunologic alterations in FM which may be the consequence of chronic stress and pain or causally involved in the development of this disorder. The endocannabinoid system has been shown to play a pivotal role in mammalian nociception, is activated under stressful conditions and can be an important signaling pathway for immune modulation. The endocannabinoid system could therefore be involved in the complex pathophysiology of FM. We tested this hypothesis by evaluating the effects of stress hormones and the endocannabinoid anandamide on neutrophil function in patients with FM. We determined plasma levels of catecholamines, cortisol and anandamide in 22 patients with primary FM and 22 age- and sex-matched healthy controls. Neutrophil function was characterized by measuring the hydrogen peroxide (H2O2) release (oxidative stress) and the ingestion capabilities of neutrophils (microbicidal function). FM patients had significantly higher norepinephrine and anandamide plasma levels. Neutrophils of FM patients showed an elevated spontaneous H2O2 production. The ability of neutrophils to adhere was negatively correlated with serum cortisol levels. Adhesion and phagocytosis capabilities of neutrophils correlated positively with anandamide plasma levels. In conclusion, patients with FM might benefit from pharmacologic manipulation of endocannabinoid signaling which should be tested in controlled studies. Topics: Arachidonic Acids; Cannabinoid Receptor Modulators; Case-Control Studies; Endocannabinoids; Epinephrine; Female; Fibromyalgia; Humans; Hydrogen Peroxide; Male; Middle Aged; Neutrophils; Norepinephrine; Oxidative Stress; Phagocytosis; Polyunsaturated Alkamides; Receptor, Cannabinoid, CB2; Research Design; Severity of Illness Index; Surveys and Questionnaires; Zymosan | 2008 |